Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

ZMIZ1 Variants Cause a Syndromic Neurodevelopmental Disorder.

Carapito R, Ivanova EL, Morlon A, Meng L, Molitor A, Erdmann E, Kieffer B, Pichot A, Naegely L, Kolmer A, Paul N, Hanauer A, Tran Mau-Them F, Jean-Marçais N, Hiatt SM, Cooper GM, Tvrdik T, Muir AM, Dimartino C, Chopra M, Amiel J, Gordon CT, Dutreux F, Garde A, Thauvin-Robinet C, Wang X, Leduc MS, Phillips M, Crawford HP, Kukolich MK, Hunt D, Harrison V, Kharbanda M; Deciphering Developmental Disorders Study; University of Washington Center for Mendelian Genomics, Smigiel R, Gold N, Hung CY, Viskochil DH, Dugan SL, Bayrak-Toydemir P, Joly-Helas G, Guerrot AM, Schluth-Bolard C, Rio M, Wentzensen IM, McWalter K, Schnur RE, Lewis AM, Lalani SR, Mensah-Bonsu N, Céraline J, Sun Z, Ploski R, Bacino CA, Mefford HC, Faivre L, Bodamer O, Chelly J, Isidor B, Bahram S.

Am J Hum Genet. 2019 Feb 7;104(2):319-330. doi: 10.1016/j.ajhg.2018.12.007. Epub 2019 Jan 10.

2.

Dual effects of constitutively active androgen receptor and full-length androgen receptor for N-cadherin regulation in prostate cancer.

Cottard F, Madi-Berthélémy PO, Erdmann E, Schaff-Wendling F, Keime C, Ye T, Kurtz JE, Céraline J.

Oncotarget. 2017 May 29;8(42):72008-72020. doi: 10.18632/oncotarget.18270. eCollection 2017 Sep 22.

3.

[Androgen receptor variants in prostate cancer].

Schreyer E, Barthélémy P, Cottard F, Ould Madi-Berthélémy P, Schaff-Wendling F, Kurtz JE, Céraline J.

Med Sci (Paris). 2017 Aug-Sep;33(8-9):758-764. doi: 10.1051/medsci/20173308021. Epub 2017 Sep 18. Review. French.

4.

[Academic carriers in oncology and radiotherapy: Explanations for the readers of Bulletin du Cancer].

Soria JC, Bastian G, Bolotine L, Calais G, Céraline J, de Cremoux P, Espié M, Karayan-Tapon L, Laprie A, Mazeron JJ, Négrier S, Roché H.

Bull Cancer. 2016 Sep;103(9):719-29. doi: 10.1016/j.bulcan.2016.07.004. Epub 2016 Aug 23. French. No abstract available.

PMID:
27561824
5.

[The level of evidence for the use of biomarkers in the early detection of prostate cancer].

Lamy PJ, Gauchez AS, Salomon L, Haugh M, Ceraline J, Fulla Y, Georges A, Larré S, Loric S, Luporsi E, Martin PM, Mazerolles C, Molinié V, Mongiat-Artus P, Piffret J, Thuillier F, Perrin P, Rebillard X; Groupe de biologie de la prostate.

Ann Biol Clin (Paris). 2016 Mar-Apr;74(2):227-32. doi: 10.1684/abc.2016.1128. Review. French.

6.

Implication of NPM1 phosphorylation and preclinical evaluation of the nucleoprotein antagonist N6L in prostate cancer.

Destouches D, Sader M, Terry S, Marchand C, Maillé P, Soyeux P, Carpentier G, Semprez F, Céraline J, Allory Y, Courty J, De La Taille A, Vacherot F.

Oncotarget. 2016 Oct 25;7(43):69397-69411. doi: 10.18632/oncotarget.8043.

7.

Osteoblasts promote castration-resistant prostate cancer by altering intratumoral steroidogenesis.

Hagberg Thulin M, Nilsson ME, Thulin P, Céraline J, Ohlsson C, Damber JE, Welén K.

Mol Cell Endocrinol. 2016 Feb 15;422:182-191. doi: 10.1016/j.mce.2015.11.013. Epub 2015 Nov 14.

8.

Reversible amyloid fiber formation in the N terminus of androgen receptor.

Asencio-Hernández J, Ruhlmann C, McEwen A, Eberling P, Nominé Y, Céraline J, Starck JP, Delsuc MA.

Chembiochem. 2014 Nov 3;15(16):2370-3. doi: 10.1002/cbic.201402420. Epub 2014 Sep 11.

PMID:
25212277
9.

Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer.

Terry S, Maillé P, Baaddi H, Kheuang L, Soyeux P, Nicolaiew N, Ceraline J, Firlej V, Beltran H, Allory Y, de la Taille A, Vacherot F.

Neoplasia. 2013 Jul;15(7):761-72.

10.

Constitutively active androgen receptor variants upregulate expression of mesenchymal markers in prostate cancer cells.

Cottard F, Asmane I, Erdmann E, Bergerat JP, Kurtz JE, Céraline J.

PLoS One. 2013 May 2;8(5):e63466. doi: 10.1371/journal.pone.0063466. Print 2013.

11.

A novel regulation of PSMA and PSA expression by Q640X AR in 22Rv1 and LNCaP prostate cancer cells.

Ben Jemaa A, Sallami S, Céraline J, Oueslati R.

Cell Biol Int. 2013 May;37(5):464-70. doi: 10.1002/cbin.10055. Epub 2013 Feb 18.

PMID:
23418075
12.

Risk of hormone escape in a human prostate cancer model depends on therapy modalities and can be reduced by tyrosine kinase inhibitors.

Guyader C, Céraline J, Gravier E, Morin A, Michel S, Erdmann E, de Pinieux G, Cabon F, Bergerat JP, Poupon MF, Oudard S.

PLoS One. 2012;7(8):e42252. doi: 10.1371/journal.pone.0042252. Epub 2012 Aug 6.

13.

New strategies for medical management of castration-resistant prostate cancer.

Asmane I, Céraline J, Duclos B, Rob L, Litique V, Barthélémy P, Bergerat JP, Dufour P, Kurtz JE.

Oncology. 2011;80(1-2):1-11. doi: 10.1159/000323495. Epub 2011 May 16. Review.

PMID:
21577012
14.

A designed cell-permeable aptamer-based corepressor peptide is highly specific for the androgen receptor and inhibits prostate cancer cell growth in a vector-free mode.

Reeb CA, Gerlach C, Heinssmann M, Prade I, Ceraline J, Roediger J, Roell D, Baniahmad A.

Endocrinology. 2011 Jun;152(6):2174-83. doi: 10.1210/en.2011-0149. Epub 2011 Apr 12.

PMID:
21486935
15.

Role of cationic channel TRPV2 in promoting prostate cancer migration and progression to androgen resistance.

Monet M, Lehen'kyi V, Gackiere F, Firlej V, Vandenberghe M, Roudbaraki M, Gkika D, Pourtier A, Bidaux G, Slomianny C, Delcourt P, Rassendren F, Bergerat JP, Ceraline J, Cabon F, Humez S, Prevarskaya N.

Cancer Res. 2010 Feb 1;70(3):1225-35. doi: 10.1158/0008-5472.CAN-09-2205. Epub 2010 Jan 26.

16.

Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line.

Marcias G, Erdmann E, Lapouge G, Siebert C, Barthélémy P, Duclos B, Bergerat JP, Céraline J, Kurtz JE.

Hum Mutat. 2010 Jan;31(1):74-80. doi: 10.1002/humu.21138.

PMID:
19830810
17.

Hormone escape is associated with genomic instability in a human prostate cancer model.

Legrier ME, Guyader C, Céraline J, Dutrillaux B, Oudard S, Poupon MF, Auger N.

Int J Cancer. 2009 Mar 1;124(5):1103-11. doi: 10.1002/ijc.24073.

18.

N-terminal polyglutamine-containing fragments inhibit androgen receptor transactivation function.

Schiffer NW, Céraline J, Hartl FU, Broadley SA.

Biol Chem. 2008 Dec;389(12):1455-66. doi: 10.1515/BC.2008.169.

PMID:
18844449
19.

Pleiotropic functional properties of androgen receptor mutants in prostate cancer.

Bergerat JP, Céraline J.

Hum Mutat. 2009 Feb;30(2):145-57. doi: 10.1002/humu.20848. Review.

PMID:
18800375
20.

Specific properties of a C-terminal truncated androgen receptor detected in hormone refractory prostate cancer.

Lapouge G, Marcias G, Erdmann E, Kessler P, Cruchant M, Serra S, Bergerat JP, Céraline J.

Adv Exp Med Biol. 2008;617:529-34. doi: 10.1007/978-0-387-69080-3_53.

PMID:
18497078
21.

A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions.

Jagla M, Fève M, Kessler P, Lapouge G, Erdmann E, Serra S, Bergerat JP, Céraline J.

Endocrinology. 2007 Sep;148(9):4334-43. Epub 2007 May 31.

PMID:
17540719
22.

Unexpected paracrine action of prostate cancer cells harboring a new class of androgen receptor mutation--a new paradigm for cooperation among prostate tumor cells.

Lapouge G, Erdmann E, Marcias G, Jagla M, Monge A, Kessler P, Serra S, Lang H, Jacqmin D, Bergerat JP, Céraline J.

Int J Cancer. 2007 Sep 15;121(6):1238-44.

23.

Unfaithfulness and promiscuity of a mutant androgen receptor in a hormone-refractory prostate cancer.

Monge A, Jagla M, Lapouge G, Sasorith S, Cruchant M, Wurtz JM, Jacqmin D, Bergerat JP, Céraline J.

Cell Mol Life Sci. 2006 Feb;63(4):487-97.

PMID:
16456618
24.

Conflicting effects of caffeine on apoptosis and clonogenic survival of human K1 thyroid carcinoma cell lines with different p53 status after exposure to cisplatin or UVc irradiation.

Deplanque G, Céraline J, Lapouge G, Dufour P, Bergerat JP, Klein-Soyer C.

Biochem Biophys Res Commun. 2004 Feb 20;314(4):1100-6.

PMID:
14751246
25.

Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer.

Céraline J, Cruchant MD, Erdmann E, Erbs P, Kurtz JE, Duclos B, Jacqmin D, Chopin D, Bergerat JP.

Int J Cancer. 2004 Jan 1;108(1):152-7.

26.

A yeast-based functional assay for the detection of the mutant androgen receptor in prostate cancer.

Céraline J, Erdmann E, Erbs P, Deslandres-Cruchant M, Jacqmin D, Duclos B, Klein-Soyer C, Dufour P, Bergerat JP.

Eur J Endocrinol. 2003 Jan;148(1):99-110.

PMID:
12534363
27.

Sensitivity to cisplatin treatment of human K1 thyroid carcinoma cell lines with altered p53 function.

Céraline J, Deplanque G, Noël F, Natarajan-Amé S, Bergerat JP, Klein-Soyer C.

Cancer Chemother Pharmacol. 2003 Jan;51(1):91-5. Epub 2002 Nov 13.

PMID:
12497212
28.

Anti-angiogenic effects of the thienopyridine SR 25989 in vitro and in vivo in a murine pulmonary metastasis model.

Mah-Becherel MC, Céraline J, Deplanque G, Chenard MP, Bergerat JP, Cazenave JP, Klein-Soyer C.

Br J Cancer. 2002 Mar 4;86(5):803-10.

29.

Caffeine and the G2/M block override: a concept resulting from a misleading cell kinetic delay, independent of functional p53.

Deplanque G, Céraline J, Mah-Becherel MC, Cazenave JP, Bergerat JP, Klein-Soyer C.

Int J Cancer. 2001 Nov 1;94(3):363-9.

30.

A new flow cytometric method to follow DNA gap filling during nucleotide excision repair of UVc-induced damage.

Vincent F, Ceraline J, Goldblum S, Klein-Soyer C, Bergerat JP.

Cytometry. 2001 Oct 1;45(2):96-101.

31.

Geraniol, a component of plant essential oils, inhibits growth and polyamine biosynthesis in human colon cancer cells.

Carnesecchi S, Schneider Y, Ceraline J, Duranton B, Gosse F, Seiler N, Raul F.

J Pharmacol Exp Ther. 2001 Jul;298(1):197-200.

PMID:
11408542
32.

p53-independent regulation of cyclin B1 in normal human fibroblasts during UV-induced G2-arrest.

Vincent F, Deplanque G, Ceraline J, Duclos B, Bergerat JP.

Biol Cell. 1999 Dec;91(9):665-74.

PMID:
10668097
33.

[Relationships between p53 induction, cell cycle arrest and survival of normal human fibroblasts following DNA damage].

Ceraline J, Deplanque G, Duclos B, Limacher JM, Vincent F, Goldblum S, Bergerat JP.

Bull Cancer. 1997 Nov;84(11):1007-16. Review. French.

34.

Inactivation of p53 in normal human cells increases G2/M arrest and sensitivity to DNA-damaging agents.

Céraline J, Deplanque G, Duclos B, Limacher JM, Hajri A, Noel F, Orvain C, Frébourg T, Klein-Soyer C, Bergerat JP.

Int J Cancer. 1998 Jan 30;75(3):432-8.

35.

Angiogenesis inhibitor SR 25989 upregulates thrombospondin-1 expression in human vascular endothelial cells and foreskin fibroblasts.

Klein-Soyer C, Céraline J, Orvain C, de la Salle C, Bergerat JP, Cazenave JP.

Biol Cell. 1997 Jul;89(4):295-307.

PMID:
9447704
36.

Alternative splicing of the dopamine D2 receptor directs specificity of coupling to G-proteins.

Guiramand J, Montmayeur JP, Ceraline J, Bhatia M, Borrelli E.

J Biol Chem. 1995 Mar 31;270(13):7354-8.

Supplemental Content

Loading ...
Support Center